argenex SE $ARGX Shares Sold by Bamco Inc. NY

Bamco Inc. NY lowered its stake in argenex SE (NASDAQ:ARGX) by 15.3% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 180,733 shares of the company’s stock after selling 32,667 shares during the period. Bamco Inc. NY owned approximately 0.30% of argenex worth $99,624,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently modified their holdings of ARGX. Millennium Management LLC boosted its stake in shares of argenex by 316.9% during the 1st quarter. Millennium Management LLC now owns 268,604 shares of the company’s stock worth $158,977,000 after acquiring an additional 204,180 shares in the last quarter. Adage Capital Partners GP L.L.C. boosted its position in shares of argenex by 114.3% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 297,113 shares of the company’s stock valued at $163,775,000 after purchasing an additional 158,476 shares during the period. Franklin Resources Inc. boosted its position in shares of argenex by 103.9% in the 2nd quarter. Franklin Resources Inc. now owns 279,803 shares of the company’s stock valued at $154,233,000 after purchasing an additional 142,606 shares during the period. BNP Paribas Financial Markets increased its stake in argenex by 1,203.4% in the 1st quarter. BNP Paribas Financial Markets now owns 133,359 shares of the company’s stock worth $78,931,000 after purchasing an additional 123,127 shares in the last quarter. Finally, Braidwell LP raised its holdings in argenex by 99.2% during the 1st quarter. Braidwell LP now owns 160,849 shares of the company’s stock worth $95,201,000 after buying an additional 80,083 shares during the period. Institutional investors and hedge funds own 60.32% of the company’s stock.

argenex Stock Down 1.3%

ARGX stock opened at $877.94 on Friday. The company has a 50 day moving average of $863.28 and a two-hundred day moving average of $716.27. The company has a market cap of $54.05 billion, a price-to-earnings ratio of 37.70, a PEG ratio of 0.89 and a beta of 0.37. argenex SE has a 12-month low of $510.05 and a 12-month high of $934.62.

argenex (NASDAQ:ARGX) last posted its quarterly earnings results on Thursday, October 30th. The company reported $4.40 EPS for the quarter, beating the consensus estimate of $4.37 by $0.03. argenex had a net margin of 41.58% and a return on equity of 29.78%. The business had revenue of $1.12 billion for the quarter, compared to analysts’ expectations of $1.07 billion. On average, research analysts anticipate that argenex SE will post 3.13 EPS for the current year.

Analyst Upgrades and Downgrades

ARGX has been the subject of several recent analyst reports. Jefferies Financial Group set a $818.00 target price on shares of argenex and gave the stock a “buy” rating in a report on Tuesday, August 26th. Morgan Stanley upped their price target on shares of argenex from $1,070.00 to $1,110.00 and gave the company an “overweight” rating in a research report on Thursday, December 4th. Weiss Ratings reiterated a “hold (c)” rating on shares of argenex in a research report on Wednesday, October 8th. JPMorgan Chase & Co. boosted their target price on shares of argenex from $925.00 to $1,100.00 and gave the company an “overweight” rating in a research note on Monday, December 8th. Finally, Wells Fargo & Company raised their target price on argenex from $1,095.00 to $1,316.00 and gave the stock an “overweight” rating in a research report on Thursday. One investment analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $968.83.

argenex Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.